Maitri Enterprises Limited reported a standalone net profit of ₹18.80 lakh for the quarter ended June 30, 2026 (Q1FY26), marking a reversal from the net loss of ₹68.35 lakh recorded in the corresponding period of FY25. While the parent company returned to profitability, the group’s consolidated results showed a net loss of ₹46.34 lakh, widening from the consolidated loss of ₹69.68 lakh in Q1FY25.

The company’s revenue from operations fell 15.6% year-on-year to ₹520.42 lakh, down from ₹616.57 lakh in Q1FY25. This decline was primarily attributed to a drop in sales of pharmaceutical goods, which contracted by 43.1% to ₹109.37 lakh. Conversely, the sale of services segment saw a marginal decline of 3.1% to ₹411.05 lakh.

Standalone vs Consolidated Performance

The divergence between standalone and consolidated results highlights operational pressures within the group structure. While the standalone entity managed to reduce its total expenses to ₹495.37 lakh against an income of ₹522.04 lakh, the consolidated entity faced higher costs. Consolidated total expenses rose to ₹558.97 lakh, exceeding total income of ₹520.50 lakh by ₹38.47 lakh before tax.

In the standalone books, cost of materials consumed decreased significantly to ₹454.86 lakh from ₹318.87 lakh in the prior year, but this was offset by a reduction in inventory changes, which swung from a positive contribution of ₹17.30 lakh in Q1FY25 to a negative ₹271.88 lakh in Q1FY26. Other expenses remained relatively stable at ₹166.82 lakh compared to ₹168.34 lakh in the previous year.

What the Numbers Show

A critical divergence exists between the performance of the two operating segments on a consolidated basis. The 'Sale of Services' segment generated a positive segment result of ₹56.71 lakh, maintaining its profitability despite lower revenues. In contrast, the 'Pharmaceutical Goods' segment incurred a significant loss of ₹65.08 lakh, compared to a loss of ₹23.44 lakh in Q1FY25. This deepening loss in the pharmaceutical segment, coupled with unallocated losses of ₹30.10 lakh, drove the overall consolidated pre-tax loss. The data suggests that while the service arm remains resilient, the goods distribution business is facing margin compression or increased working capital costs that are not fully reflected in the top-line revenue decline alone.

Auditor Qualification on Receivables

The consolidated financial results were subject to a qualified review conclusion by the statutory auditors, Dinesh R. Thakkar & Co. The qualification stems from insufficient audit evidence regarding the recoverability of trade receivables amounting to ₹163.63 lakh in the wholly-owned subsidiary, BSA Marketing Private Limited. These balances have been outstanding for over three years out of total trade receivables of ₹241.53 lakh as of June 30, 2026.

Management recognized an impairment loss of ₹62.42 lakh for the quarter based on Expected Credit Loss (ECL) assessments under Ind AS 109. However, auditors could not verify the recoverability of the remaining unimpaired balance, leaving open the possibility of further adjustments to the carrying amount of receivables and the group’s financial results.

Corporate Appointments

During its board meeting held on August 12, 2026, Maitri Enterprises approved several key appointments:

• Internal Auditor: CA Bunty Rajkumar Talreja was appointed for the financial year 2026-27.
• Secretarial Auditor: M/s. Nisarg Sharma & Associates was appointed to fill the casual vacancy left by M/s. SJV & Associates, whose peer review certificate had expired. The new auditor will serve until the conclusion of the ensuing Annual General Meeting.
• Company Secretary: Ms. Rajshree Jain was appointed as Company Secretary and Compliance Officer effective August 12, 2026.

The trading window for dealing in the company’s securities will reopen 48 hours after the declaration of these results.

Maitri Enterprises Limited will convene its second board meeting for FY26 on May 28, 2026, to consider and approve the audited financial results for the quarter and year ended March 31, 2026. The meeting will be held at the company's registered office in Ahmedabad to review the financial performance and audit report for the specified period under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The board will also address any other business with the permission of the Chairman and the majority of directors. The intimation was submitted to BSE Limited under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended in 2018, the company's trading window has been closed since April 01, 2026. This closure applies to all designated persons, connected persons, and their immediate relatives. The window will reopen 48 hours after the declaration of the financial results following the board meeting.

Key Meeting Details

The company has ensured that all procedural requirements for the meeting and the trading window closure have been communicated to the stock exchanges. The signatory, Jaikishan R. Ambwani, Managing Director, confirmed that the contents of the intimation were approved by the Board of Directors.